Sabal Trust CO boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 141,150 shares of the medical research company’s stock after acquiring an additional 1,444 shares during the quarter. Amgen makes up approximately 2.5% of Sabal Trust CO’s holdings, making the stock its 24th biggest holding. Sabal Trust CO’s holdings in Amgen were worth $24,546,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Baker Ellis Asset Management LLC acquired a new position in Amgen during the 3rd quarter valued at about $108,000. Jackson Grant Investment Advisers Inc. lifted its position in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares during the period. Phocas Financial Corp. acquired a new position in Amgen during the 2nd quarter valued at about $110,000. Omnia Family Wealth LLC lifted its position in Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares during the period. Finally, Salem Investment Counselors Inc. lifted its position in Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 36 shares during the period. 79.50% of the stock is currently owned by hedge funds and other institutional investors.
AMGN has been the topic of a number of research reports. Vetr downgraded shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a research report on Wednesday, January 3rd. Royal Bank of Canada reiterated a “hold” rating and issued a $189.00 price target on shares of Amgen in a research report on Wednesday, January 24th. Piper Jaffray Companies reiterated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. BidaskClub downgraded shares of Amgen from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Cann reiterated a “buy” rating and issued a $205.00 price target on shares of Amgen in a research report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $191.26.
Shares of Amgen stock opened at $169.43 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market cap of $122,084.81, a P/E ratio of 13.47, a price-to-earnings-growth ratio of 2.08 and a beta of 1.37. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the business posted $2.89 earnings per share. equities analysts anticipate that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be issued a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a yield of 3.12%. Amgen’s dividend payout ratio (DPR) is currently 205.45%.
Amgen declared that its Board of Directors has authorized a stock repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Sabal Trust CO” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3299281/amgen-inc-amgn-shares-bought-by-sabal-trust-co.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.